EUVIMEDEUVIMED entdecken
Crossref

Activating Tumor‐Selective Liquid Metal Nanomedicine through Galvanic Replacement

Junjie Yan, Jinqiang Wang, Xinyu Wang, Donghui Pan, Chen Su, Junxia Wang, Mengzhen Wang, Jianjun Xiong, Yu Chen, Lizhen Wang, Yuping Xu, Chongyang Chen und 2 weitere

Advanced Materials · 2024

DOI: 10.1002/adma.202307817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Junjie Yan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Center, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Insti…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Prodrugs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced chemotherapeutic strategies including prodrug and nanocatalytic medicine have significantly advanced tumor‐selective theranostics, but delicate prodrug screening, tedious synthesis, low degradability/biocompatibility of inorganic components, and unsatisfied reaction activity complicate treatment efficacies. Here, the intrinsic anticancer bioactivity of liquid metal nanodroplets (LMNDs) is explored through galvanic replacement. By utilizing a mechano‐degradable ligand, the resultant size of the aqueous LMND is unexpectedly controlled as small as ≈20 nm (LMND20). It is demonstrated that LMND20 presents excellent tumor penetration and biocompatibility and activates tumor‐selective carrier‐to‐drug conversion, synchronously depleting Cu 2+ ions and producing Ga 3+ ions through galvanic replacement. Together with abundant generation of reactive oxygen species, multiple anticancer pathways lead to selective apoptosis and anti‐angiogenesis of breast cancer cells. Compared to the preclinical/clinical anticancer drugs of tetrathiomolybdate and Ga(NO 3 ) 3 , LMND20 administration significantly improves the therapeutic efficacy and survival in a BCap‐37 xenograft mouse model, yet without obvious side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsProdrugsHumansAnimalsMiceNanomedicineMetalsIonsCell Line, Tumor

Stichwörter der Autor:innen

cancer therapycopper depletiondrug deliverygalvanic replacementliquid metalnanomedicine

Substanzen

Antineoplastic AgentsProdrugsMetalsIons

Autor:innen und Institutionen

  • Molecular Imaging Center, Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
  • National Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • Research Institute for Reproductive Health and Genetic Diseases, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, 214002, China.
  • Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • Department of General Surgery, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.

ORCID-Profile: Zhen Gu

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Natural Science Foundation of Jiangsu Province
  • Six Talent Peaks Project in Jiangsu Province
  • Wuxi Science and Technology Development Foundation
  • Jiangsu Provincial Medical Innovation Team
  • National Key Research and Development Program of China

Zitieren

APA

Yan, J., Wang, J., Wang, X., Pan, D., Su, C., Wang, J., Wang, M., Xiong, J., Chen, Y., Wang, L., Xu, Y., Chen, C., Yang, M., & Gu, Z. (2024). Activating Tumor‐Selective Liquid Metal Nanomedicine through Galvanic Replacement. Advanced Materials. https://doi.org/10.1002/adma.202307817

Vancouver

Yan J, Wang J, Wang X, Pan D, Su C, Wang J, et al. Activating Tumor‐Selective Liquid Metal Nanomedicine through Galvanic Replacement. Advanced Materials. 2024. doi:10.1002/adma.202307817

BibTeX
@article{Yan2024,
  author = {Yan, Junjie and Wang, Jinqiang and Wang, Xinyu and Pan, Donghui and Su, Chen and Wang, Junxia and Wang, Mengzhen and Xiong, Jianjun and Chen, Yu and Wang, Lizhen and Xu, Yuping and Chen, Chongyang and Yang, Min and Gu, Zhen},
  title = {Activating Tumor‐Selective Liquid Metal Nanomedicine through Galvanic Replacement},
  journal = {Advanced Materials},
  year = {2024},
  doi = {10.1002/adma.202307817}
}
Kostenlos starten →